Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM5TB76)

Drug Name
DACRA 089 Drug Info
Synonyms KBP-089
Indication
Disease Entry ICD 11 Status REF
Type 2 diabetes 5A11 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM5TB76

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Amylin receptor (IAPPR) TTAT87F CALCR_HUMAN-RAMP1_HUMAN/RAMP2_HUMAN/RAMP3_HUMAN Agonist [2]
Calcitonin receptor (CALCR) TTLWS2O CALCR_HUMAN Agonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Calcitonin receptor (CALCR) DTT CALCR 5.326 4.489 4.213 5.07
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Type 2 diabetes
ICD Disease Classification 5A11
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Calcitonin receptor (CALCR) DTT CALCR 7.52E-03 0.17 2.26
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03907202) A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DM. U.S. National Institutes of Health.
2 A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference. Br J Pharmacol. 2017 Apr;174(7):591-602.